Document:

Exhibit 10.7

 Exhibit 10.7 

 
 

 
  

			
	Michael A. Martino	  	November 9, 2011
	PO Box 5000 PMB 190	  	
	Rancho Santa Fe, CA 92067	  	

 Re: Carve-out Plan Benefits 
 Dear Mr. Martino, 
 This letter confirms our agreement with respect to
certain benefits related to your services as Chief Executive Officer of Ambit Biosciences Corporation (“Ambit”). 

Carve-Out Benefits. 
 (i)
Success Fee. If at any time while you are serving as Chief Executive Officer pursuant to that certain Employment Agreement dated on even date herewith (the “Employment Agreement”) (or during the six (6) month
period after termination of your service as Chief Executive Officer if such service shall have been terminated without Cause (as defined in the Employment Agreement)) and prior to the Success Fee Expiration Date (defined below), a Covered
Transaction (as defined in the Employment Agreement) that either (a) meets the Price Minimum (defined below) or (b) for which the Ambit board of directors (the “Board”) has waived the Price Minimum, shall have been
consummated, you shall be eligible to receive, subject to the terms of this letter agreement, a payment (the “Success Fee”) in an amount equal to your Vested Equity Percentage Interest (defined below) multiplied by the
Aggregate Gross Proceeds (defined below) actually paid or distributed pursuant to such Covered Transaction to Ambit’s stockholders and holders of options, warrants or other rights to Preferred Stock or Common Stock by reason of their ownership
thereof and/or paid or distributed directly to Ambit. Notwithstanding the foregoing, however, the amount of any Success Fee payable to you shall be reduced dollar- for-dollar by any Aggregate Gross Proceeds actually paid to you pursuant to such
Covered Transaction by reason of your equity position in Ambit, whether by common stock ownership, the exercise or cash-out of stock options or otherwise, including but not limited to any Bonus Option Substitute Benefits (as defined in the
Employment Agreement), if applicable. In no event will the Success Fee be payable with respect to any Covered Transaction other than the first Covered Transaction that occurs following the date of this letter agreement. 

(ii) Payment of Success Fee. Any Success Fee to which you become entitled hereunder shall be paid in the same forms (i.e., in
cash, stock and/or other property) and in the same proportions as the Aggregate Gross Proceeds are paid by the acquirer in such 

  
 Ambit
Biosciences Corporation 
 4215 Sorrento Valley Boulevard 
 San Diego, CA 92121 
 tel 858-334-2100 fax 858-334-2198 

www.ambitbio.com 

1 

 
Covered Transaction to Ambit’s stockholders or Ambit, as applicable. Any securities that are issued to you as part of a Success Fee payment will be subject to the same or similar
restrictions as imposed by the acquiring company on the securities distributed to Ambit’s stockholders or Ambit, as applicable, on the terms set forth in the agreement pursuant to which the Covered Transaction occurs. Except as provided in
subsections (iii) and (iv) below, any Success Fee to which you become entitled hereunder shall be paid within ten (10) business days after the Aggregate Gross Proceeds are paid to Ambit’s stockholders and holders of options,
warrants or other rights to Preferred or Common Stock Preferred or, in the case of an asset sale, are paid to Ambit, but in no event later than thirty (30) days following the Closing (defined below) of the Covered Transaction. 

(iii) Payments of Unvested Contingent Consideration Amounts. If and to the extent the Aggregate Gross
Proceeds include any Contingent Consideration (as defined in the Employment Agreement), the Success Fee payable with respect thereto (i.e., a pro-rata portion of the Success Fee) will be Unvested Consideration (defined below). In addition, and for
clarity, if at the closing of a Covered Transaction the Price Threshold (as defined in the Employment Agreement) has not been met but by reason of the payment of Contingent Consideration following the Closing the Price Threshold is thereafter met
(such applicable date is the “Success Fee Vesting Date”), the Company and its successor shall ensure that you receive a Success Fee catch-up payment, and any future related payments of Contingent Consideration, as if the
Price Threshold had been met upon the Closing. If applicable, such initial catch-up payment shall be made to you no later than thirty (30) days following the Success Fee Vesting Date. If the Conditions (as defined in the Employment Agreement)
to payment of a portion of the Contingent Consideration are satisfied, the related portion of the Unvested Consideration will be paid to you within ten (10) business days after such portion of the Contingent Consideration is paid to Ambit or
its stockholders but in no event later than the earlier of (A) thirty (30) days following the date on which the applicable Condition is satisfied, or (B) the fifth (5th) anniversary of the Closing. If as of the fifth (5th) anniversary of the Closing any Unvested Consideration
would otherwise continue to remain subject to outstanding Conditions on payment, you shall be paid such portion of the Unvested Consideration related to such Conditions, subject to any reduction made by the Board based on the Fair Market Value (as
of the fifth (5th) anniversary of the Closing) of the
Unvested Consideration as a result of the existence of the Conditions (that is, the present value of the pro-rata portion of the Success Fee that may be earned upon satisfaction of the Conditions), in a lump sum on the fifth (5th) anniversary of the Closing. If the Price Threshold is not met
prior to the fifth (5th) anniversary of the Closing,
then in no event will you receive payment of any Success Fee. 
 (iv) The following provisions in this subsection
(iv) shall apply only if the Price Threshold is met upon the Closing. To the extent that a Condition, when applied to the Success Fee, would not constitute a “substantial risk of forfeiture” (as defined in Treasury
Regulations Section 1.409A-1(d)), such that the Unvested Consideration related to such Condition would not be reasonably likely to be payable in compliance with either Treasury Regulation Section 1.409A-1(b)(4) or Treasury Regulation
Section 1.409A-3(i)(5)(iv)(A), or to the extent the Board determines the Unvested Consideration is not otherwise payable 

  
 2 

 
in compliance with or under an exemption from Section 409A, you shall be paid the portion of the Unvested Consideration related to such Condition, subject to any reduction made by the Board
based on the Fair Market Value (as of the Closing) of the Unvested Consideration as a result of the existence of the Conditions (that is, the present value of the Success Fee that may be earned upon satisfaction of the Conditions), in a lump sum on
the thirtieth (30th) day following the Closing.

 (v) Additional Definitions. For all purposes of this letter agreement, the following terms have the following
meanings: 
 “Aggregate Gross Proceeds” means, in the case of a Covered Transaction other than the sale
of all or substantially all of Ambit’s assets, the sum of (i) the aggregate amount actually paid or distributed, directly or indirectly, to Ambit stockholders as consideration for those securities in consummation of such Covered
Transaction plus (ii) the aggregate amount paid in such Covered Transaction to the holders of stock options, warrants or other stock rights relating to Ambit’s Preferred or Common Stock as consideration for those securities in consummation
of such Covered Transaction. The amount of the Aggregate Gross Proceeds determined as aforesaid shall be determined in good faith by the Board. In the case of a Covered Transaction that is the sale of all or substantially all of Ambit’s assets,
“Aggregate Gross Proceeds” shall mean the amount determined by the Board in good faith that would be distributed to the holders of (i) Ambit’s Preferred and Common Stock and (ii) stock options, warrants or
other stock rights relating to Ambit’s Preferred or Common Stock if all of the assets of Ambit were sold for their fair market value and all of the liabilities paid (and adequate provision made for liabilities of Ambit) and any net proceeds
distributed to such holders. 
 “Code” means Internal Revenue Code of 1986, as amended. 

“Closing” will mean the initial closing of the Covered Transaction as defined in the definitive agreement
executed in connection with the Covered Transaction. In the case of a series of transactions constituting a Covered Transaction, “Closing” means the first closing that satisfies the threshold of the definition for a Covered
Transaction. 
 “Fair Market Value” will be the value determined by the Board as of the applicable date
in its sole discretion in accordance with Section Code 409A to the extent applicable, and such determination will be final and binding. 
 “Price Minimum” means that the assets distributable or payable to the holders of Series D-2 Preferred Stock and Series D-3 Preferred Stock (or the holders of shares of Common Stock
issued upon conversion of the Series D-2 Preferred Stock and Series D-3 Preferred Stock) pursuant to a Covered Transaction have a fair market value as determined in good faith by the Board at least equal to, in the aggregate, the product of
(A) $0.89 (as adjusted for any stock splits, dividends and the like after the date hereof) and (B) the total number of shares of Series D-2 Preferred Stock and Series D-3 Preferred Stock (or

  
 3 

 
such shares of Common Stock, as applicable) outstanding immediately prior to such Covered Transaction. If the assets so distributable or payable with respect to a Covered Transaction do not equal
or exceed the Price Minimum as of the closing thereof but subsequently, by reason of the payment of Contingent Consideration, do equal or exceed the Price Minimum, then such Covered Transaction shall be deemed, retroactively as of such closing, to
have met the Price Minimum (and the Company and any successor shall ensure that all applicable payments shall be made to you as if the Price Minimum had been met as of such closing). 

“Section 409A” means Section 409A of the Code and the Treasury Regulations and other guidance issued
thereunder and any state law of similar effect. 
 “Success Fee Expiration Date” means the date that
Ambit shall have consummated an initial public offering of shares of Ambit’s common stock for the account of Ambit pursuant to a Registration Statement on Form S-l (or successor form) filed with and declared effective by the United States
Securities and Exchange Commission. 
 “Unvested Consideration” means the portion of the Success Fee
that is subject to the same Conditions on payment of Contingent Consideration as are imposed on Ambit or its stockholders generally. 
 “Vested Equity Percentage Interest” means the percentage of the fully-diluted capitalization of Ambit as of immediately prior to the closing of a Covered Transaction represented by
all shares of Ambit’s Common Stock then owned by you or that are issuable upon the conversion, exercise, or exchange of any outstanding options, warrants or other securities then owned by you, but in each case only to the extent such Common
Stock, options, warrants and other securities are (i) then vested and not subject to any repurchase right in favor of Ambit or (ii) will become vested and not subject to any such repurchase right by reason of the consummation of such
Covered Transaction. 
 Parachute Payment. 
 In the event the benefits provided by this letter agreement (the “Payment”), when aggregated with any other payments or benefits received by you, would (i) constitute a
“parachute payment” within the meaning of Section 280G of the Code and (ii) but for this sentence, be subject to the excise tax imposed by Section 4999 of the Code (the “Excise Tax”),
then such Payment shall be reduced to the Reduced Amount. The “Reduced Amount” shall be either (x) the largest portion of the Payment that would result in no portion of the Payment being subject to the Excise Tax or
(y) the largest portion, up to and including the total, of the Payment, whichever amount, after taking into account all applicable federal, state and local income taxes and the Excise Tax (all computed at the highest applicable marginal rate),
results in your receipt, on an after-tax basis, of the greater amount of the Payment notwithstanding that all or some portion of the Payment may be subject to the Excise Tax. If a reduction in payments or benefits constituting a
“parachute payment” is necessary so that the Payment equals the Reduced Amount, such 

  
 4 

 
reduction shall occur in the following order: first the cancellation of the accelerated vesting of any stock awards as to which no portion of the Aggregate Gross Proceeds would be payable, then
the reduction of your Success Fee and finally the cancellation of any other stock awards you hold at the time. In the event that accelerated vesting of your stock awards is to be reduced, such acceleration of vesting shall be cancelled in the
reverse order of the date of grant of your stock awards unless you elect in writing a different order for cancellation. 
 The
accounting firm engaged by Ambit for general tax purposes shall perform the foregoing calculations. Ambit shall bear all expenses with respect to the determinations by such accounting firm required to be made hereunder. 

The accounting firm engaged to make the determinations hereunder shall provide its calculations, together with detailed supporting
documentation, to you and Ambit within seven (7) business days after the date on which your right to a Payment is triggered (if requested at that time by you or Ambit) or at such earlier time as requested by you or Ambit. If the accounting firm
determines that no Excise Tax is payable with respect to a Payment, either before or after the application of the Reduced Amount, it shall furnish you and Ambit with an opinion reasonably acceptable to you that no Excise Tax will be imposed with
respect to such Payment. Any good faith determinations of the accounting firm made hereunder shall be final, binding and conclusive upon you and Ambit. 
 In the event the payment of any amounts pursuant to this letter agreement would result in your being subject to an Excise Tax (without giving effect to any reduction in such payments to the Reduced
Amount), at your request in your sole discretion, Ambit will use its commercially reasonable best efforts to obtain a vote of the stockholders of Ambit approving such payments in the manner set forth in Section 280G(b)(5)(B) of the Code and the
Treasury Regulations issued thereunder such that the payments would not be subject to the Excise Tax if the required stockholder approval is obtained. In the event you so request that such a vote be taken, you agree to execute a waiver and enter
into such additional agreements as may be reasonably requested by Ambit in relation thereto, including, without limitation, agreeing that the portion of such payments that would otherwise, if made, result in your becoming liable for the Excise Tax
will not be made if the required stockholder approval is not obtained. 
 Section 409A Compliance. 

It is intended that each installment of the payments provided under this letter agreement is a separate “payment” for purposes
Section 1.409A-2(b)(2)(i) of the Treasury Regulations. For the avoidance of doubt, it is intended that the Success Fee payment satisfies, to the greatest extent possible, the exemption from the application of Section 409A provided under
Treasury Regulations Section 1.409A-1(b)(4) and, to the extent not so exempt, that the Success Fee payment complies, and the terms of this letter agreement be interpreted to the greatest extent possible as consistent, with the requirements of

  
 5 

 
Treasury Regulations Section 1.409A-3(i)(5)(iv)(A) – that is, as “transaction-based compensation.” or as payable upon a permitted specified date and/or payment event in
compliance with the requirements of Section 409A. 
 If the foregoing correctly conforms to your understanding of the
agreement between you and Ambit, please sign and date the enclosed copy of this letter and return it to us. 
  

	
	Very truly yours,
	
	AMBIT BIOSCIENCES, INC.
	
	 /s/ Alan Fuhrman

	Alan Fuhrman
	Chief Financial Officer
	
	Accepted and agreed:
	
	 /s/ Michael A. Martino

	Michael A. Martino

  
 6Exhibit 10.8

 Exhibit 10.8 
 September 13, 2010 
 Mr. Alan Fuhrman 

4667 Torrey Circle G101 
 San Diego, CA 92130

 Dear Alan: 
 I am very pleased to
make you a formal offer to join Ambit Biosciences Corporation (the “Company”). This letter sets forth the principal terms of an offer for you to join the Company. 

 

			
	Initial Position:	  	Chief Financial Officer
	  
 Start Date:
	  	  
 The tentative start date, to be agreed upon by you, will be
Monday, October 11, 2010

	  
 Reporting Relationship:
	  	  
 You will initially report to Dr. Alan J. Lewis, President &
Chief Executive Officer

		
	  
 Initial Responsibilities:
	  	  
 Responsibilities will include, but not limited
to:

		  	  

•      Directing Ambit financial functions to help attain the company’s
financial goals.
  

•      Developing and auditing financial policies and programs following good
accounting practices.
  

•      Building and maintaining strong relationships with the financial
community.
  

•      Developing long term financial plans for the organization.

 

•      Formulating and executing the Company’s plan for building a world
class biopharmaceutical business to support the Company’s goals of building a deep pipeline and development cancer drugs.
  

•      Performing other duties as assigned.

	  
 Location:
	  	  
 You will be based initially in San Diego,
California.

	  
 Compensation:
	  	  
 You will be a regular full-time, exempt employee and receive a
gross monthly salary of $22,916.67 ($275,000 on an annualized basis), which will be paid semi-monthly in arrears in accordance with the Company’s normal payroll procedures.

 Alan Fuhrman 
 September 13, 2010 
  Page
 2
 
  

			
	Equity:	  	Following commencement of your full-time employment we will recommend to the Stock Option Committee of the Board of Directors of the Company that you be granted options to
purchase 300,000 shares of Common Stock of the Company at the current fair market value as determined by the Board. These options will vest according to the following schedule: 25% shall fully vest on the first anniversary of your start date and the
remainder shall vest at a rate of one forty-eighth ( 1/48) each month thereafter until fully vested on the fourth anniversary of your start date.
		
	Incentive Bonus:	  	You will be eligible to be considered for a discretionary annual incentive bonus, initially targeted at 30% of your annual base salary. You will receive annual performance
reviews which, subject to your actual performance, may result in one or more of the following: i) salary adjustments; ii) merit increases; and, iii) additional option grants.
		
	Benefits:	  	The beginning of the month following your start as a full-time employee you and your eligible dependants will be able to enroll in one of three medical plans and a dental plan
sponsored by the Company. You will be provided a summary of these plans and upon commencement of full-time employment, enrollment forms will be provided. Vision, Life, AD&D, and LTD insurance is also provided for full-time
employees.
		
		  	You will begin accruing paid personal leave (PPL) according to company guidelines beginning with your first pay period as a full-time employee. In your first year as a full-time
employee you will accrue 20 days of PPL. The Company also has established 12 paid holidays per calendar year. You will also be eligible for enrollment in a 401(k) plan and a flexible benefit plan.
		
	Severance:	  	In the event of (a) termination of your employment by the Company or its successor without cause (as defined below), or (b) termination (or constructive termination) of your
employment with the Company or its successor by you or the Company following a change of control transaction because you were not offered a position in the greater San Diego, California metropolitan area involving status, duties, salary and benefits
substantially equivalent to those enjoyed by you in your then existing position with the Company, the Company shall, in case of (a) or (b) listed above: Continue to pay you as severance payment your salary (as in effect at such time) over the one
(1) year period following the date of such termination (the “Severance Period”), accelerate by one (1) year the vesting of your option grants and/or restricted stock then held by you and continue your then existing employee benefits over
the Severance Period, and, in the case of (b) listed above: Accelerate 100% of the vesting of your option grants and/or restricted stock then held by you. The provision of each of the above benefits is conditioned upon your execution of a general
release of claims in favor of the company, in the form attached to this letter. You agree that in the event of a termination under the circumstances described above, you will not be entitled to any other compensation or benefits.
		
		  	For Severance purposes Cause means, the occurrence of any of the following: (i) your conviction of any felony or any crime involving fraud or dishonesty that
has a material adverse effect on the Company; (ii) your participation (whether by affirmative act or omission) in a fraud, act of dishonesty or other act of misconduct against the Company and/or a parent or subsidiary; (iii) conduct by you
which, based upon a good faith and reasonable factual investigation by the Company demonstrates such Employee’s gross unfitness to serve; (iv) your violation of any statutory or fiduciary duty, or duty

 Alan Fuhrman 
 September 13, 2010 
  Page
 3
 
  

			
	  	 	of loyalty, owed to the Company and/or a parent or subsidiary; (v) your breach of any material term of any
material contract between you and the Company and/or a
parent or subsidiary; and (vi) your repeated violation
of any material Company policy.

 You should be aware that your
employment with the Company is for no specified period and constitutes at-will employment. As a result, you are free to resign at any time, for any reason or for no reason. Similarly, the Company is free to conclude its employment relationship with
you at any time, with or without cause, and with or without notice. 
 For purposes of federal immigration law, you will be required to provide
to the Company documentary evidence of your identity and eligibility for employment in the United States. Such documentation must be provided to us within three (3) business days of your date of hire, or our employment relationship with you may
be terminated. 
 As a Company employee, you will be expected to abide by company rules and regulations. You will be specifically required to
sign an acknowledgment that you have read and understand the company rules of conduct, which is included in our employee handbook. You will also be expected to sign and comply with an Employee Proprietary Information and Inventions Agreement which
requires, among other provisions, the assignment of patent rights to any invention made during your employment at the Company and non-disclosure of proprietary information. 
 To indicate your acceptance of the Company’s offer, please sign and date this letter in the space provided below and return it to Emily Derr, Human Resources Manager. A duplicate original is enclosed
for your records. This letter, along with the agreement relating to proprietary rights between you and the Company, set forth the terms of your employment with the Company and supersede any prior representations or agreements, whether written or
oral. This letter may not be modified or amended except by a written agreement, signed by an officer of the Company and by you. If a response is not received by September 24, 2010, this offer will be considered null and void. 

We look forward to continuing working with you at Ambit Biosciences Corporation. We hope that you will decide continue building this world-class company.

  

	
	Sincerely,
	
	Ambit Biosciences Corporation
	
	/s/ Alan J. Lewis
	
	Alan J. Lewis, Ph.D.
	President and Chief Executive Officer

  

	
	ACCEPTED AND AGREED TO this
	
	14 Day of September, 2010
	
	 /s/ Alan Fuhrman

	Alan Fuhrman

 Enclosures 
 Duplicate Original Letter 

 AMBIT BIOSCIENCES CORPORATION 

SECOND AMENDMENT TO OFFER LETTER OF ALAN FUHRMAN 
 This amendment (the “Second Amendment”) is made by and between Alan Fuhrman (“Employee”) and Ambit Biosciences Corporation (the
“Company,” and together with Employee, the “Parties”), effective as of December 21, 2012. 
 WHEREAS, the Parties entered into an employment offer letter agreement dated September 13, 2010 (the “Offer Letter”) which was amended and supplemented by a
severance and carve-out letter agreement between the Parties dated January 12, 2012 (the “First Amendment” and, collectively with the Offer Letter, the “Agreement”); and 

WHEREAS, the Company and Employee desire to amend the Offer Letter to clarify certain timing requirements regarding
Employee’s execution of a release of claims in favor of the Company, and to clarify that the benefits provided under the Offer Letter are intended to be exempt from, or compliant with Section 409A of the Internal Revenue Code of 1986, as
amended (the “Code”) and the regulations and other guidance thereunder and any state law of similar effect (collectively “Section 409A”). 

NOW, THEREFORE, for good and valuable consideration, Employee and the Company agree that the Offer Letter is hereby amended to add
a new section entitled “Section 409A Compliance” following the “Severance” section of the Offer Letter, as follows: 
 “Section 409A Compliance. The severance benefits are intended to qualify for an exemption from application of Section 409A of the Internal Revenue Code of 1986, as amended and the
regulations and other guidance thereunder and any state law of similar effect (collectively “Section 409A”) or to comply with its requirements to the extent necessary to avoid adverse personal tax consequences
under Section 409A, and any ambiguities herein shall be interpreted accordingly. Notwithstanding anything to the contrary herein, the following provisions of this paragraph apply to the extent severance benefits provided herein are subject to
Section 409A. Severance benefits shall not commence until you have a “separation from service” for purposes of Section 409A. Each installment of severance benefits is a separate “payment” for purposes of Treas. Reg.
Section 1.409A-2(b)(2)(i), and the severance benefits are intended to satisfy the exemptions from application of Section 409A provided under Treasury Regulations Sections 1.409A-1(b)(4), 1.409A-1(b)(5) and 1.409A-1(b)(9). However, if such
exemptions are not available and you are, upon separation from service, a “specified employee” for purposes of Section 409A, then, solely to the extent necessary to avoid adverse personal tax consequences under Section 409A, the
timing of the severance benefits payments shall be delayed until the earlier of (i) six (6) months and one day after your separation from service, or (ii) your death. 

You shall receive severance benefits only if you execute and return to the Company, within the applicable time period set forth therein
but in no event more than forty-five (45) days following the date of separation from service, a release of claims in favor of the Company in substantially the form attached to this letter (or such other form as the Company will provide at such
time) and permit such release to become effective in accordance with its terms (such latest permitted date on which the release may become effective, the “Release Deadline”). If the severance benefits are not
covered by one or more exemptions from the application of Section 409A and the release could become effective in the calendar year following the calendar year in which you separate from service, the release will not be deemed effective any
earlier than the Release Deadline. None of the severance benefits will be paid or otherwise delivered prior to the effective date of the release. Except to the minimum extent that payments must be delayed because you are a “specified
employee” or until the effectiveness of the release, all amounts will be paid as soon as practicable in accordance with the Company’s normal payroll practices.” 

 Full Force and Effect. To the extent not expressly amended hereby, the Agreement
shall remain in full force and effect. 
 Entire Agreement. This Second Amendment and the Agreement constitute the full
and entire understanding and agreement between the Parties with regard to the subjects hereof and thereof. This Second Amendment may be amended at any time only by mutual written agreement of the Parties. 

Counterparts. This Second Amendment may be executed in counterparts, all of which together shall constitute one instrument, and
each of which may be executed by less than all of the parties to this Second Amendment. 
 Governing Law. This Second
Amendment will be governed by the laws of the State of California (with the exception of its conflict of laws provisions). 

IN WITNESS WHEREOF, each of the Parties has executed this Second Amendment, in the case of the Company by its duly authorized
officer, on the date first written above. 
  

					
	AMBIT BIOSCIENCES CORPORATION	 		 	EMPLOYEE
			
	 /s/ Michael A. Martino
	 		 	 /s/ Alan Fuhrman

	Michael A. Martino	 		 	Alan Fuhrman
	President and Chief Executive Officer	 		 	

  
 -2-

Source: [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00212-of-00352.parquet"}, [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00212-of-00352.parquet"}]]